Tailoring Obesity Treatment Trial

NCT06619015 on ClinicalTrials.gov · last registry update 2026-04-17

Withdrawn before anyone was enrolled. Completed 1 April 2025. semaglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: WITHDRAWN
Phase: P2/P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Esbjerg Hospital - University Hospital of Southern Denmark
Sponsor type: Other
Enrollment: 0
Started: 2025-04-01
Primary completion: 2025-04-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in kilocalorie (kCal) consumption at ad libitum meal test, from baseline, to after 26 weeks of semaglutide of which the last two weeks is with the addition of either pramlintide or placebo

Conditions studied

Obesity · Appetite Regulation · PreDiabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.